• Je něco špatně v tomto záznamu ?

Polygenic risk for immuno-metabolic markers and specific depressive symptoms: A multi-sample network analysis study

N. Kappelmann, D. Czamara, N. Rost, S. Moser, V. Schmoll, L. Trastulla, J. Stochl, S. Lucae, CHARGE inflammation working group, EB. Binder, GM. Khandaker, J. Arloth

. 2021 ; 95 (-) : 256-268. [pub] 20210329

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural

Perzistentní odkaz   https://www.medvik.cz/link/bmc21018405

BACKGROUND: About every fourth patient with major depressive disorder (MDD) shows evidence of systemic inflammation. Previous studies have shown inflammation-depression associations of multiple serum inflammatory markers and multiple specific depressive symptoms. It remains unclear, however, if these associations extend to genetic/lifetime predisposition to higher inflammatory marker levels and what role metabolic factors such as Body Mass Index (BMI) play. It is also unclear whether inflammation-symptom associations reflect direct or indirect associations, which can be disentangled using network analysis. METHODS: This study examined associations of polygenic risk scores (PRSs) for immuno-metabolic markers (C-reactive protein [CRP], interleukin [IL]-6, IL-10, tumour necrosis factor [TNF]-α, BMI) with seven depressive symptoms in one general population sample, the UK Biobank study (n = 110,010), and two patient samples, the Munich Antidepressant Response Signature (MARS, n = 1058) and Sequenced Treatment Alternatives to Relieve Depression (STAR*D, n = 1143) studies. Network analysis was applied jointly for these samples using fused graphical least absolute shrinkage and selection operator (FGL) estimation as primary analysis and, individually, using unregularized model search estimation. Stability of results was assessed using bootstrapping and three consistency criteria were defined to appraise robustness and replicability of results across estimation methods, network bootstrapping, and samples. RESULTS: Network analysis results displayed to-be-expected PRS-PRS and symptom-symptom associations (termed edges), respectively, that were mostly positive. Using FGL estimation, results further suggested 28, 29, and six PRS-symptom edges in MARS, STAR*D, and UK Biobank samples, respectively. Unregularized model search estimation suggested three PRS-symptom edges in the UK Biobank sample. Applying our consistency criteria to these associations indicated that only the association of higher CRP PRS with greater changes in appetite fulfilled all three criteria. Four additional associations fulfilled at least two consistency criteria; specifically, higher CRP PRS was associated with greater fatigue and reduced anhedonia, higher TNF-α PRS was associated with greater fatigue, and higher BMI PRS with greater changes in appetite and anhedonia. Associations of the BMI PRS with anhedonia, however, showed an inconsistent valence across estimation methods. CONCLUSIONS: Genetic predisposition to higher systemic inflammatory markers are primarily associated with somatic/neurovegetative symptoms of depression such as changes in appetite and fatigue, consistent with previous studies based on circulating levels of inflammatory markers. We extend these findings by providing evidence that associations are direct (using network analysis) and extend to genetic predisposition to immuno-metabolic markers (using PRSs). Our findings can inform selection of patients with inflammation-related symptoms into clinical trials of immune-modulating drugs for MDD.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21018405
003      
CZ-PrNML
005      
20210830100001.0
007      
ta
008      
210728s2021 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.bbi.2021.03.024 $2 doi
035    __
$a (PubMed)33794315
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Kappelmann, Nils $u Department of Translational Research in Psychiatry, Max-Planck-Institute of Psychiatry, Munich, Germany; International Max Planck Research School for Translational Psychiatry (IMPRS-TP), Munich, Germany. Electronic address: n.kappelmann@gmail.com
245    10
$a Polygenic risk for immuno-metabolic markers and specific depressive symptoms: A multi-sample network analysis study / $c N. Kappelmann, D. Czamara, N. Rost, S. Moser, V. Schmoll, L. Trastulla, J. Stochl, S. Lucae, CHARGE inflammation working group, EB. Binder, GM. Khandaker, J. Arloth
520    9_
$a BACKGROUND: About every fourth patient with major depressive disorder (MDD) shows evidence of systemic inflammation. Previous studies have shown inflammation-depression associations of multiple serum inflammatory markers and multiple specific depressive symptoms. It remains unclear, however, if these associations extend to genetic/lifetime predisposition to higher inflammatory marker levels and what role metabolic factors such as Body Mass Index (BMI) play. It is also unclear whether inflammation-symptom associations reflect direct or indirect associations, which can be disentangled using network analysis. METHODS: This study examined associations of polygenic risk scores (PRSs) for immuno-metabolic markers (C-reactive protein [CRP], interleukin [IL]-6, IL-10, tumour necrosis factor [TNF]-α, BMI) with seven depressive symptoms in one general population sample, the UK Biobank study (n = 110,010), and two patient samples, the Munich Antidepressant Response Signature (MARS, n = 1058) and Sequenced Treatment Alternatives to Relieve Depression (STAR*D, n = 1143) studies. Network analysis was applied jointly for these samples using fused graphical least absolute shrinkage and selection operator (FGL) estimation as primary analysis and, individually, using unregularized model search estimation. Stability of results was assessed using bootstrapping and three consistency criteria were defined to appraise robustness and replicability of results across estimation methods, network bootstrapping, and samples. RESULTS: Network analysis results displayed to-be-expected PRS-PRS and symptom-symptom associations (termed edges), respectively, that were mostly positive. Using FGL estimation, results further suggested 28, 29, and six PRS-symptom edges in MARS, STAR*D, and UK Biobank samples, respectively. Unregularized model search estimation suggested three PRS-symptom edges in the UK Biobank sample. Applying our consistency criteria to these associations indicated that only the association of higher CRP PRS with greater changes in appetite fulfilled all three criteria. Four additional associations fulfilled at least two consistency criteria; specifically, higher CRP PRS was associated with greater fatigue and reduced anhedonia, higher TNF-α PRS was associated with greater fatigue, and higher BMI PRS with greater changes in appetite and anhedonia. Associations of the BMI PRS with anhedonia, however, showed an inconsistent valence across estimation methods. CONCLUSIONS: Genetic predisposition to higher systemic inflammatory markers are primarily associated with somatic/neurovegetative symptoms of depression such as changes in appetite and fatigue, consistent with previous studies based on circulating levels of inflammatory markers. We extend these findings by providing evidence that associations are direct (using network analysis) and extend to genetic predisposition to immuno-metabolic markers (using PRSs). Our findings can inform selection of patients with inflammation-related symptoms into clinical trials of immune-modulating drugs for MDD.
650    _2
$a antidepresiva $x terapeutické užití $7 D000928
650    _2
$a C-reaktivní protein $x analýza $7 D002097
650    12
$a deprese $x genetika $7 D003863
650    12
$a depresivní porucha unipolární $x farmakoterapie $x genetika $7 D003865
650    _2
$a lidé $7 D006801
650    _2
$a zánět $x farmakoterapie $x genetika $7 D007249
650    _2
$a multifaktoriální dědičnost $7 D020412
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
700    1_
$a Czamara, Darina $u Department of Translational Research in Psychiatry, Max-Planck-Institute of Psychiatry, Munich, Germany
700    1_
$a Rost, Nicolas $u Department of Translational Research in Psychiatry, Max-Planck-Institute of Psychiatry, Munich, Germany; International Max Planck Research School for Translational Psychiatry (IMPRS-TP), Munich, Germany
700    1_
$a Moser, Sylvain $u Department of Translational Research in Psychiatry, Max-Planck-Institute of Psychiatry, Munich, Germany; International Max Planck Research School for Translational Psychiatry (IMPRS-TP), Munich, Germany
700    1_
$a Schmoll, Vanessa $u Department of Translational Research in Psychiatry, Max-Planck-Institute of Psychiatry, Munich, Germany
700    1_
$a Trastulla, Lucia $u Department of Translational Research in Psychiatry, Max-Planck-Institute of Psychiatry, Munich, Germany
700    1_
$a Stochl, Jan $u Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom; Department of Kinanthropology, Charles University, Prague, Czech Republic
700    1_
$a Lucae, Susanne $u Max-Planck-Institute of Psychiatry, Munich, Germany
700    1_
$a Binder, Elisabeth B $u Department of Translational Research in Psychiatry, Max-Planck-Institute of Psychiatry, Munich, Germany
700    1_
$a Khandaker, Golam M $u Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom; Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, United Kingdom; MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom; Centre for Academic Mental Health, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom
700    1_
$a Arloth, Janine $u Department of Translational Research in Psychiatry, Max-Planck-Institute of Psychiatry, Munich, Germany; Institute of Computational Biology, Helmholtz Zentrum Munich, Neuherberg, Germany
710    2_
$a CHARGE inflammation working group
773    0_
$w MED00000839 $t Brain, behavior, and immunity $x 1090-2139 $g Roč. 95, č. - (2021), s. 256-268
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33794315 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830100001 $b ABA008
999    __
$a ok $b bmc $g 1689503 $s 1138849
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 95 $c - $d 256-268 $e 20210329 $i 1090-2139 $m Brain, behavior, and immunity $n Brain Behav Immun $x MED00000839
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...